Table: SymBio Pharmaceuticals -Q1 group results

SymBio Pharmaceuticals

07/05/2024 09:00

May 7 (Reuters)- 
             SymBio Pharmaceuticals Limited 
             CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                   3 months ended      3 months ended        Year to  
                  Mar 31, 2024        Mar 31, 2023      Dec 31, 2024  
                     LATEST             YEAR-AGO           LATEST     
                     RESULTS             RESULTS          FORECAST    
  Sales              597 mln              1.54              2.62      
                   (-61.3 pct)         (-33.3 pct)       (-53.1 pct)  
  Operating       loss 806 mln           51 mln           loss 3.70   
                                       (-89.9 pct)                    
  Recurring       loss 727 mln           48 mln           loss 3.52   
                                       (-89.9 pct)                    
  Net             loss 777 mln            4 mln           loss 3.63   
                                       (-97.3 pct)                    
  EPS            loss 18.03 yen         0.11 yen       loss 84.15 yen 
  EPS Diluted                           0.11 yen                      
  Ann Div                                  NIL               NIL      
  -Q2 div                                  NIL               NIL      
  -Q4 div                                  NIL               NIL      
  
  NOTE - SymBio Pharmaceuticals Limited. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4582.T